News | April 27, 2010

Statin Gains New European Indication to Prevent Cardiovascular Events

April 27, 2010 – A popular statin gained a new indication today in the European Union for prevention of major cardiovascular events in patients who are at high risk of having a first cardiovascular event.
This new indication for Crestor (rosuvastatin) is based on subgroup data from the landmark JUPITER study, which evaluated the impact of rosuvastatin 20 mg on reducing major cardiovascular events in a previously unstudied population. A post-hoc analysis of this subgroup data showed a significant reduction in the combined endpoint of heart attacks, strokes and cardiovascular deaths amongst the high-risk patients within JUPITER.

This new indication allows rosuvastatin to be prescribed to patients to prevent cardiovascular events, including heart attacks and strokes. Clinical studies have previously shown rosuvastatin was effective at lowering low-density lipoprotein cholesterol (LDL-C), had a significant effect on raising high-density lipoprotein cholesterol (HDL-C) and slowed the progression of atherosclerosis.

In JUPITER, rosuvastatin 20 mg was well tolerated in nearly 9,000 patients. There was no difference between treatment groups for major adverse events. There was a small increase in physician reported diabetes, which is in line with data from other large placebo controlled statin trials.

High-risk patients were defined in the study as having a Framingham risk score more than 20 percent

The JUPITER Trial
JUPITER was a long-term, randomized, double-blind, placebo-controlled, large-scale study of 17,802 patients designed to determine if rosuvastatin 20 mg decreased the risk of heart attack, stroke and other cardiovascular events in patients with low to normal LDL-C but at increased cardiovascular risk as identified by age and elevated high-sensitivity C-reactive protein (hsCRP). The majority of patients had at least one other risk factor including hypertension, low HDL-C, family history of premature coronary heart disease (CHD) or smoking. hsCRP is a recognized marker of inflammation, which is associated with an increased risk of atherosclerotic cardiovascular events. JUPITER was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in patients treated with Crestor. There was a small increase in physician reported diabetes (2.8 percent in patients taking Crestor vs. 2.3 percent in patients taking placebo) observed in the JUPITER trial.

JUPITER is a part of AstraZeneca's extensive GALAXY clinical trials program, designed to address unanswered questions in statin research. Currently, more than 65,000 patients have been recruited from 55 countries worldwide to participate in GALAXY.

Crestor has received regulatory approval in more than 100 countries, and 19 million patients have been prescribed the drug worldwide. Data from clinical trials and real world use shows that the safety profile for Crestor is in line with other marketed statins.
For more information: www.astrazeneca.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Overlay Init